Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STUP-001 in Chronic Spinal Cord Injury
NCT06922890Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of STUP-001 in spinal cord injury (SCI) (2 arms), sponsored by Yonsei University. Primary endpoint: Dose-limit toxicity evaluation post STUP-001 administration at 4 weeks. Started Jul 2025; status: recruiting.
02
Drugs
STUP-001
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06922890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922890.